Mesoblast Limited (ASX: MSB) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Mesoblast Limited Chart and Price Data
Fundamentals Data provided by Morningstar.
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Mesoblast Limited (ASX: MSB)
Latest News
Share Market News
Why the Mesoblast (ASX:MSB) share price is sinking 11% lower
Healthcare Shares
These are 8 of the best performing ASX healthcare shares of 2020 so far
Share Market News
Which shares will benefit from trillions of dollars in new global stimulus?
Share Gainers
Why the Mesoblast (ASX:MSB) share price is charging higher today
Share Fallers
Why Fisher & Paykel Healthcare, Mesoblast, Splitit, & WiseTech are dropping lower
⏸️ ASX Shares
The Mesoblast (ASX:MSB) share price jumped 33% in November and could go even higher
Share Market News
ASX 200 flat on Wednesday
Share Gainers
Why Laybuy, Mesoblast, Sandfire, & Telix shares are charging higher
Share Market News
ASX 200 down 0.2%: Zip's November update, Mesoblast jumps, Westpac's asset sale
Share Gainers
Mesoblast (ASX:MSB) share price jumps 19% on FDA update
⏸️ ASX Shares
Flight Centre and Mesoblast were among the most traded shares on the ASX last week
Share Gainers
2 ASX 200 healthcare shares that outperformed in November
Frequently Asked Questions
-
No, Mesoblast does not pay shareholder dividends at this time.
-
Yes, Mesoblast is listed on the ASX and the US Nasdaq under the ticker code NASDAQ: MESO.
-
Mesoblast Ltd listed on the ASX on 16 December 2004.
MSB ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Mesoblast Limited
Mesoblast Ltd (ASX: MSB) is a clinical-stage biotechnology company. It develops and commercialises allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care.
Its portfolio of Phase 3 product candidates includes its flagship remestemcel-L for the treatment of steroid-refractory acute graft versus host disease (SR-aGVHD) as well as moderate to severe acute respiratory distress syndrome (ARDS). Its other candidates include REVASCOR® for advanced chronic heart failure and MPC-06-ID for chronic low back pain due to degenerative disc disease. These cell therapy candidates are towards the latter stages of their clinical trial pipelines.
Mesoblast has locations in Australia, the United States, and Singapore and is dual-listed on the ASX and the US Nasdaq (NASDAQ: MESO).
